文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

少菌型结核导致低流行区Xpert MTB/RIF Ultra利福平耐药检测阳性预测值偏低

Paucibacillary Tuberculosis Drives the Low Positive Predictive Value of Xpert MTB/RIF Ultra for Rifampicin Resistance Detection in Low-Prevalence Settings.
PubMed 文献 · Clin Infect Dis · 2025-01-01

卢旺达全国性研究纳入2021年12月至2024年1月Ultra诊断的129例利福平耐药结核患者,重复Ultra及rpoB测序和表型药敏验证。仅41例(32%)重复检测结果一致,88例未确认;初始Ultra极低菌量患者假耐药风险显著增高(风险比8.20,95%CI 3.56-18.85,P<.001)。

要点

  • Ultra初诊利福平耐药患者中仅32%(41/129)重复检测结果一致。
  • 极低菌量患者假耐药风险是其他菌量类别的8.20倍(95%CI 3.56-18.85)。
  • 53%(54/101)有参考检测的初诊耐药患者接受了不必要的耐药治疗。

核心结论

  • Ultra是快速检测利福平耐药结核的有价值工具,但在低流行区其耐药检测阳性预测值偏低主要由极低菌量样本驱动。
  • 随着规划扩大主动病例发现和早期检测无症状疾病,极低菌量检出的结核比例将增加,诊断算法需调整以避免不必要的利福平耐药结核治疗。

研究设计与样本

  • 卢旺达全国性研究,纳入2021年12月至2024年1月经Ultra诊断为利福平耐药结核的患者,进行重复Ultra检测,并辅以rpoB基因测序和表型药敏试验作为参考标准。

主要发现

  • 129例初诊利福平耐药患者中,仅41例(32%)重复Ultra结果一致,88例(68%)未确认耐药。
  • 41例确认病例中40例(98%)有参考检测,均验证为真耐药;88例未确认病例中61例(69%)有参考检测,其中7例(11%)为真耐药,54例(89%)为利福平敏感结核。
  • 初始Ultra极低菌量的55例患者中89%为假耐药,假耐药风险显著高于其他菌量类别合计(风险比8.20;95%CI 3.56-18.85;P<.001)。
  • 有参考检测的101例初诊耐药患者中,53%(54/101)接受了不必要的利福平耐药结核治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Xpert MTB/RIF Ultra (Ultra) aimed to improve the specificity in identifying rifampicin-resistant tuberculosis (RR-TB), compared to Xpert MTB/RIF. METHODS: In a nationwide study in Rwanda, patients diagnosed with RR-TB by Ultra between December 2021 and January 2024 underwent repeat Ultra testing, complemented by rpoB gene sequencing and phenotypic drug-susceptibility testing (pDST), serving as reference tests. RESULTS: Of 129 patients initially diagnosed with RR-TB by Ultra, only 41 (32%) had concordant rifampicin results upon repeat Ultra testing. The remaining 88 patients (68%) had unconfirmed resistance on repeat Ultra. Reference testing was available for 40 (98%) of 41 confirmed cases, all verified as true RR-TB. Among 88 unconfirmed cases, reference testing was available for 61 (69%), with 7 (11%) confirmed as true RR-TB, whereas 54 (89%) were found to have rifampicin-susceptible TB. Notably, 89% of 55 patients with very low bacillary loads on their initial Ultra had false RR-TB results, a significantly higher risk of false resistance compared to other bacillary load categories combined (risk ratio: 8.20; 95% confidence interval [CI]: 3.56-18.85; P < .001). Consequently, 53% (54/101) of initial RR patients with available reference testing received unnecessary RR-TB treatment. CONCLUSIONS: Ultra represents a valuable tool for rapid RR-TB detection; however, in low prevalence settings its low positive predictive value for RR detection is largely driven by samples with very low bacillary loads. As programs expand active case-finding and early detection of asymptomatic disease, the proportion of TB detected with very low bacillary load will increase. Diagnostic algorithms require adjustments to prevent unnecessary RR-TB treatment.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cuella-Martin I, Hakizayezu F, Ahmed A, et al. Paucibacillary Tuberculosis Drives the Low Positive Predictive Value of Xpert MTB/RIF Ultra for Rifampicin Resistance Detection in Low-Prevalence Settings. Clin Infect Dis. 2025. PMID: 40120087. doi:10.1093/cid/ciaf132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。